An automated method on analysis of blood steroids using liquid chromatography tandem mass spectrometry: Application to population screening for congenital adrenal hyperplasia in newborns

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2076-2084

  Dhillon, Kuldeep ^a   Ho, Thomson ^a   Rich, Patti ^a   Xu, Dadong ^a   Lorey, Fred ^a   She, Jianwen ^a   Bhandal, Ajit ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

17 hydroxyprogestrone; Congenital adrenal hyperplasia; Enzyme immunoassay; LC MS MS; Newborn screening; Steroids

Indexed keywords

ANDROSTENEDIONE; HYDROCORTISONE; HYDROXYPROGESTERONE; STEROID;

ACCURACY; ANALYTIC METHOD; ARTICLE; AUTOMATION; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; CROSS REACTION; ELECTROSPRAY; ENZYME IMMUNOASSAY; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; NEWBORN SCREENING; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY ANALYSIS; STEROID BLOOD LEVEL; TANDEM MASS SPECTROMETRY;

ADRENAL HYPERPLASIA, CONGENITAL; AUTOMATION; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LIMIT OF DETECTION; STEROIDS; TANDEM MASS SPECTROMETRY;

EID: 80053631138     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.07.009     Document Type: Article

References (25)

1. Speiser P.W., White P.C. Congenital adrenal hyperplasia. N Engl J Med 2003, 349:776-788.
2. Forest Maguelone G. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update 2004, 10(6):469-485.
3. Technical report: congenital adrenal hyperplasia. Section on endocrinology and committee on genetics. Pediatrics 2000, 106:1511-1518.
4. White P.C., Speiser P.W. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000, 21(3):245-291.
5. Pang S.Y., Wallace M.A., Hofman L., et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988, 81:866-874.
6. White P.C. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 2009, 5:490-498.
7. Therrell B.L., Berenbaum S.A., Manter-Kapanke V., et al. Results of screening 1.9million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998, 101:583-590.
8. Brosnan P.G., Brosnan C.A., Kemp S.F., et al. Effect of newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 1999, 153:1272-1278.
9. Lacey J.M., Minutti C.Z., Magera M.J., et al. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 2004, 50:621-625.
10. Makela S.K., Ellis G. Nonspecificity of a direct 17 alpha-hydroxyprogesterone radioimmunoassay kit when used with samples from neonates. Clin Chem 1988, 34:2070-2075.
11. al Saedi S., Dean H., Dent W., Stockl E., Cronin C. Screening for congenital adrenal hyperplasia: the Delfia Screening Test overestimates serum 17-hydroxyprogesterone in preterm infants. Pediatrics 1996, 97:100-102.
12. Nordenstrom A., Wedell A., Hagenfeldt L., Marcus C., Larsson A. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics 2001, 108:E68.
13. Allen D.B., Hoffman G.L., Fitzpatrick P., Laessig R., Maby S., Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-ydroxyprogesterone levels. J Pediatr 1997, 130:128-133.
14. Wudy S.A., Wachter U.A., Homoki J., Teller W.M. 17a-Hydroxyprogesterone, 4-androstadione, and testosterone profiled by routine stable isotope dilution/gas-chromatography-mass spectrometry in plasma of children. Pediatr Res 1995, 38:76-80.
15. Deng C., Ji J., Zhang L., Zhang X. Diagnosis of congenital adrenal hyperplasia by rapid determination of 17alpha-hydroxyprogesterone in dried blood spots by gas chromatography/mass spectrometry following microwave-assisted silylation. Rapid Commun Mass Spectrom 2005, 19:2974-2978.
16. Wudy S.A., Hartmann M., Svoboda M. Determination of 17-hydroxyprogesterone in plasma by stable isotope dilution/benchtop liquid chromatography-tandem mass spectrometry. Horm Res 2000, 53:68-71.
17. Lai C.C., Tsai C.H., Tsai F.J., Wu J.Y., Lin W.D., Lee C.C. Rapid screening assay of congenital adrenal hyperplasia by measuring 17α-hydroxyprogesterone with high-performance liquid chromatography/ electrospray ionization tandem mass spectrometry from dried blood spots. J Clin Lab Anal 2002, 6:20-25.
18. Kao P.C., Machacek D.A., Magera M.J., Lacey J.M., Rinaldo P. Diagnosis of adrenal cortical dysfunction by liquid chromatography tandem mass spectrometry. Ann Clin Lab Sci 2001, 31:199-204.
19. Minutti C.Z., Lacey J.M., Magera M.J., et al. Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 2004, 89:3687-3693.
20. Janzen N., Peter M., Sander S., et al. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2007, 92:2581-2589.
21. She J., Dhillon K., Bhandal A., Lorey F., Sherwin J. Improved accuracy and precision for LC-MS/MS steroid profiling test for CAH screening. The 2007 newborn screening and genetics testing symposium by Association of Public Health Laboratories and Centers for Disease Control and Prevention, Minneapolis, MN May 7-10, 2007, 86. Poster#15.
22. De Jesús V.R., Simms D.A., Schiffer J., Kennedy M., Mei J.V., Hannon W.H. Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening. Clin Chim Acta 2010, 411:1684-1687.
23. Olgemoller B., Roscher A.A., Liebl B., Fingerhut R. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 2003, 88:5790-5794.
24. Dhillon K., Bhandal A., Xu D., Rich P., Lorey F. Modified automated isotope dilution LC-MS/MS method for CAH second tier with additional steroid profile. The 20th newborn screening and genetic testing symposium by Association of Public Health Laboratories and Centers for Disease Control and Prevention, San Antonio, TX November 3-6, 2008, 56. Poster#43.
25. Chace D.H., Hannon W.H. Impact of second-tier testing on the effectiveness of newborn screening. Clin Chem Nov 2010, 56:1653-1655.